NCT02338375Unknown早期 1 期
Clinical Trial of the Safety and Efficacy of Allogenic Umbilical Cord Blood-derived Mesenchymal Stem Cell Product With Microfracture for Osteochondral Lesion of Talus Patients
适应症
试验速览
- 阶段
- 早期 1 期
- 入组人数
- 28
- 试验地点
- 1
- 主要终点
- evaluate the efficacy of adding allogenic umbilical cord blood-derived stem cell product(Cartistem®) by American Orthopaedic Foot and Ankle Society(AOFAS) HINDFOOT/ANKLE SCALE
研究概览
简要总结
The purpose of this study is to evaluate the safety and efficacy of adding allogenic umbilical cord blood-derived stem cell product(Cartistem®) on currently standard treatment of arthroscopic curettage and microfracture for osteochondral lesion of talus.
详细描述
same as above
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 20 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Non-responder to conservative treatment for radiographically confirmed (by MRI) osteochondral lesion of talus with ankle pain and/or stiffness and less than 75 of the AOFAS score
- •Age between 20 and 70 year-old
- •Appropriate function of blood clot PT(INR) < 1.5, APTT <1.5×control
- •Appropriate renal function Creatinine ≤ 2.0 ㎎/㎗, proteinuria less than trace with Dipstick urine test
- •Appropriate hepatic function Bilirubin ≤ 2.0 ㎎/㎗, AST/ALT ≤ 100 IU/L
- •No evidence of autoimmue disorder As screening test anti-nuclear antibody and/or anti-thyroglobulin antibody, if positive rheumatologist referral needed to confirm diagnosis
- •No surgery or radiotherapy for the same ankle joint within 6 weeks
- •Female patients agreeing with maintenance of contraception during study period
- •No ligament instability greater than grade II (Grade 0 : none, Grade Ⅰ: 0~5㎜, GradeⅡ: 5~10㎜, Grade Ⅲ: >10㎜) with physical exam
- •Patients agreeing with participation in this study and signed on informed consent by their own will
排除标准
- •Degenerative ankle arthritis patients
- •Patients with autoimmune disease
- •Patients with infectious disease needed parenteral antibiotics
- •Patients with myocardial infarction, congestive heart failure, other serious heart diseases or uncontrollable hypertion
- •Patients with other serious medical illness
- •Pregnancy or breast feeding patients
- •Past history related with psychiatric illness or epilepsy
- •Alcoholic abuse
- •Heavy smoker
- •Chronic inflammatory disease including rheumatoid arthritis
- •Participants of other clinical trial within 4 weeks
- •Patients treated with immunosuppressing agents such as Cyclosporin A or azathioprine within 6 weeks
- •Unstable ankle joint(lesion site) greater than grade II at physical exam (Grade 0 : none, grade Ⅰ: 0~5㎜, GradeⅡ: 5~10㎜, Grade Ⅲ: >10㎜)
- •Other inappropriate patients determined by the prinicipal investigator
结局指标
主要结局
evaluate the efficacy of adding allogenic umbilical cord blood-derived stem cell product(Cartistem®) by American Orthopaedic Foot and Ankle Society(AOFAS) HINDFOOT/ANKLE SCALE
时间窗: Baseline, Week 4, Week 8, Week 12, Week 24, Week 48
次要结局
- evaluate the efficacy of adding allogenic umbilical cord blood-derived stem cell product(Cartistem®) by 100-mm VAS(Visual Analogue Scale)(Baseline, Week 4, Week 8, Week 12, Week 24, Week 48)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
1 期
A Study of TH-SC01 for Treating Complex Perianal Fistula in Perianal Crohn's Disease.Crohn's DiseaseNCT04939337Jinling Hospital, China24
已完成
1 期
Allogeneic Umbilical Cord Blood Therapy for StrokeStrokeNCT01884155MinYoung Kim, M.D.5
已完成
不适用
Allogeneic UCB Therapy With EPO in Children With CPCerebral PalsyNCT01991145MinYoung Kim, MD, PhD92
撤回
不适用
Allogeneic Umbilical Cord Blood Therapy for Chronic TBITraumatic Brain InjuryNCT01451528Bundang CHA Hospital
招募中
早期 1 期
Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic LeukemiaB-Cell Acute Lymphoblastic Leukemia, AdultNCT06696833The First Affiliated Hospital of Soochow University18